{"id":"colecalciferol","rwe":[{"pmid":"41235112","year":"2025","title":"Implementation of pharmacist recommendations following medication reviews in aged care.","finding":"","journal":"Frontiers in pharmacology","studyType":"Clinical Study"},{"pmid":"40461338","year":"2025","title":"Novel approach to central giant cell granuloma of the Jaw: Low-dose intralesional denosumab treatment in a case series of nine patients.","finding":"","journal":"Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery","studyType":"Clinical Study"},{"pmid":"40412099","year":"2025","title":"Effect of cholecalciferol on 25-hydroxyvitamin D in people living with HIV and vitamin D deficiency: A prospective observational study.","finding":"","journal":"Medicina clinica","studyType":"Clinical Study"},{"pmid":"40034581","year":"2025","title":"Desensitization to colecalciferol in 18 patients with immediate hypersensitivity reactions.","finding":"","journal":"The World Allergy Organization journal","studyType":"Clinical Study"},{"pmid":"39130432","year":"2024","title":"Repurposing anti-osteoporosis drugs for autoimmune diseases: A two-sample Mendelian randomization study.","finding":"","journal":"Heliyon","studyType":"Clinical Study"}],"_fda":{"id":"5cd4a682-f5e5-42fe-9151-8ecc77fe7464","set_id":"14c7bfc5-07e8-400f-b8ff-5e4794dd2805","openfda":{"rxcui":["1304559","1304564"],"spl_id":["5cd4a682-f5e5-42fe-9151-8ecc77fe7464"],"brand_name":["Infuvite Adult"],"spl_set_id":["14c7bfc5-07e8-400f-b8ff-5e4794dd2805"],"package_ndc":["54643-5649-1","54643-5657-1","54643-5659-1","54643-5650-2","54643-5661-2","54643-5663-2"],"product_ndc":["54643-5649","54643-5650"],"generic_name":["MULTIPLE VITAMINS INJECTION"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Sandoz Inc"],"application_number":["NDA021163"],"is_original_packager":[true]},"version":"18","pregnancy":["8.1 Pregnancy Risk Summary Administration of the approved recommended dose of INFUVITE ADULT in parental nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Pregnant patients should follow the U.S. Recommended Daily Allowances for pregnancy because their vitamin requirements may exceed those of nonpregnant patients. Deficiency of essential vitamins may result in adverse pregnancy outcomes (see Clinical Considerations) . Animal reproduction studies have not been conducted with INFUVITE ADULT. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo-Fetal Risk Deficiency of essential vitamins has been associated with adverse pregnancy and fetal outcomes, such as maternal folic acid deficiency and an increased risk of neural tube defects. Therefore, parenteral nutrition with multiple vitamins injection should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake."],"overdosage":["10 OVERDOSAGE Signs and symptoms of acute or chronic overdosage may be those of individual INFUVITE ADULT component toxicity. In post-marketed surveillance, overdosage with INFUVITE ADULT at two times the prescribed dose did not result in toxicity."],"description":["11 DESCRIPTION INFUVITE ADULT (multiple vitamins injection) is a sterile product consisting of two vials provided as a single dose or as a pharmacy bulk package, both intended for intravenous use for administration by intravenous infusion after dilution: INFUVITE ADULT Single Dose - two 5 mL single-dose vials labeled Vial 1 and Vial 2. INFUVITE ADULT Pharmacy Bulk Package - two vials – 1 each of Vial 1 (50 mL) and Vial 2 (50 mL Fill in 100 mL Vial). The mixed solution (100 mL) will provide ten 10 mL single doses. Each 5 mL of Vial 1 contains: Ascorbic acid (Vitamin C) 200 mg Vitamin A * (as palmitate) 3,300 IU Vitamin D 3 * (cholecalciferol) 200 IU Thiamine (Vitamin B 1 ) (as the hydrochloride) 6 mg Riboflavin (Vitamin B 2 ) (as riboflavin 5-phosphate sodium) 3.6 mg Pyridoxine HCl (Vitamin B 6 ) 6 mg Niacinamide 40 mg Dexpanthenol (as d -pantothenyl alcohol) 15 mg Vitamin E * ( dl -α-tocopheryl acetate) 10 IU Vitamin K 1 * 150 mcg *Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K. Inactive ingredients: 1.4% polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection. Each 5 mL of Vial 2 contains: Folic acid 600 mcg Biotin 60 mcg Vitamin B 12 (cyanocobalamin) 5 mcg Inactive ingredients: 30% propylene glycol, citric acid and/or sodium citrate for pH adjustment, and water for injection. INFUVITE ADULT makes available a combination of important oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E, and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins. Contains no more than 70 mcg/L of aluminum (combined Vials 1 and 2)."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied INFUVITE ADULT (multiple vitamins injection) is supplied as follows: Vial 1 (Single Dose and Pharmacy Bulk Package) is supplied as clear, yellow to orange liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a white flip-off. Vial 2 (Single Dose and Pharmacy Bulk Package) is supplied as clear, colorless to pale yellow liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a deep purple flip-off. INFUVITE ADULT Single Dose : Carton contains total ten single-dose vials NDC 54643-5649-1 Five of Vial 1 (5 mL) NDC 54643-5657-1 Five of Vial 2 (5 mL) NDC 54643-5659-1 one Vial 1 plus one Vial 2 to be used for a single dose [see Dosage and Administration ( 2.1 )]. INFUVITE ADULT Pharmacy Bulk Package: Carton contains total two vials NDC 54643-5650-2 One Vial 1 (50 mL) NDC 54643-5661-2 One Vial 2 (50 mL Fill in 100 mL Vial) NDC 54643-5663-2 Mix contents of Vial 1 with Vial 2 to provide 10 single doses [see Dosage and Administration ( 2.1 )]. Storage and Handling Minimize exposure of INFUVITE ADULT to light because vitamins A, D and riboflavin are light sensitive. Store under refrigeration, 2°C to 8°C (36°F to 46°F)."],"geriatric_use":["8.5 Geriatric Use Safety and effectiveness for geriatric use have not been established."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in children below the age of 11 years have not been established."],"effective_time":"20241106","adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other section of the labeling. • Allergic reactions to thiamine [see Warnings and Precautions ( 5.2 )] • Hypervitaminosis A [see Warnings and Precautions ( 5.3 )] The following adverse reactions have been identified during postapproval use of INFUVITE ADULT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Dermatologic: rash, erythema, pruritis CNS: headache, dizziness, agitation, anxiety Ophthalmic: diplopia Adverse reactions have included anaphylaxis and anaphylactoid reactions including shortness of breath, wheezing and angioedema, rash, erythema, pruritis, headache, dizziness, agitation, anxiety, diplopia ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ."],"contraindications":["4 CONTRAINDICATIONS INFUVITE ADULT is contraindicated in patients who have • An existing hypervitaminosis, or • A history of hypersensitivity due to any vitamins or excipients contained in this formulation. • Hypersensitivity to any of the vitamins or excipients ( 4 ) • Existing hypervitaminosis ( 4 )"],"description_table":["
Ascorbic acid (Vitamin C)200 mg
Vitamin A* (as palmitate)3,300 IU
Vitamin D3* (cholecalciferol)200 IU
Thiamine (Vitamin B1) (as the hydrochloride)6 mg
Riboflavin (Vitamin B2) (as riboflavin 5-phosphate sodium)3.6 mg
Pyridoxine HCl (Vitamin B6)6 mg
Niacinamide40 mg
Dexpanthenol (as d-pantothenyl alcohol)15 mg
Vitamin E* (dl-α-tocopheryl acetate)10 IU
Vitamin K1*150 mcg
","
Folic acid600 mcg
Biotin60 mcg
Vitamin B12 (cyanocobalamin)5 mcg
"],"drug_interactions":["7 DRUG INTERACTIONS A number of interactions between vitamins and drugs have been reported. The following are examples of these types of interactions: Effect of INFUVITE ADULT on other drugs: • Antibiotics: Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin ( 7.1 ) • Bleomycin: Ascorbic acid and riboflavin may reduce the activity of bleomycin ( 7.1 ) • Levodopa: Pyridoxine may decrease blood levels of levodopa and levodopa efficacy may decrease ( 7.1 ) • Phenytoin: Folic acid may decrease phenytoin blood levels and increase risk of seizure activity ( 7.1 ) • Methotrexate: Folic acid may decrease response to methotrexate ( 7.1 ) Effects of other drugs on INFUVITE ADULT: • Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements ( 7.2 ). • Phenytoin: May decrease folic acid concentrations ( 7.2 ) • Chloramphenicol : In patients with pernicious anemia, the hematologic response to vitamin B12 therapy may be inhibited ( 7.2 ) 7.1 Drug Interactions Affecting Co-Administered Drugs Warfarin : Vitamin K, a component of INFUVITE ADULT, antagonizes the anticoagulant action of warfarin. In patients who are co-administered warfarin and INFUVITE ADULT, blood levels of prothrombin/INR should be monitored to determine if dose of warfarin needs to be adjusted [see Warnings and Precautions ( 5.4 )]. Antibiotics : Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid decrease antibiotic activities of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin. Bleomycin : Ascorbic acid and riboflavin inactivate bleomycin in vitro , thus the activity of bleomycin may be reduced. Levodopa : Pyridoxine may increase the metabolism of levodopa (decrease blood levels of levodopa) and decrease its efficacy. Phenytoin: Folic acid may increase phenytoin metabolism and lower the serum concentration of phenytoin resulting in increased seizure activity. Methotrexate: Folic acid may decrease a patient’s response to methotrexate therapy. 7.2 Drug Interactions Affecting Vitamin Levels Hydralazine, Isoniazid: Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements. Phenytoin : Phenytoin may decrease serum folic acid concentrations. Chloramphenicol: In patients with pernicious anemia, the hematologic response to vitamin B 12 therapy may be inhibited by chloramphenicol."],"how_supplied_table":["Five of Vial 1 (5 mL)Five of Vial 2 (5 mL)
Carton contains total ten single-dose vialsNDC 54643-5649-1
NDC 54643-5657-1
NDC 54643-5659-1
","One Vial 1 (50 mL)One Vial 2 (50 mL Fill in 100 mL Vial)
Carton contains total two vialsNDC 54643-5650-2
NDC 54643-5661-2
NDC 54643-5663-2
"],"indications_and_usage":["1 INDICATIONS AND USAGE INFUVITE ADULT is a combination of vitamins indicated for the prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. INFUVITE ADULT is a combination of vitamins indicated for prevention of vitamin deficiency in adults and children aged 11 and older receiving parenteral nutrition ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Risk of Aluminum Toxicity: For at risk patients (renal failure or those with prolonged therapy), consider periodic monitoring of aluminum levels ( 5.1 ) • Allergic Reactions: To thiamine may occur ( 5.2 ) • Hypervitaminosis A : Patients with renal failure or liver disease may be at higher risk ( 5.3 ) • Decreased Anticoagulant Effect of Warfarin: Monitor INR ( 5.4 , 7.1 ) • Interferes with Megaloblastic Anemia Diagnosis: Avoid during testing for this disorder ( 5.5 ) • Risk of Vitamin Deficiencies or Excesses: Monitor blood vitamin concentrations ( 5.6 ) • False Negative Urine Glucose Tests: Due to vitamin C ( 5.7 ) 5.1 Aluminum Toxicity INFUVITE ADULT contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. To prevent aluminum toxicity periodically monitor aluminum levels with prolonged parenteral administration of INFUVITE ADULT in patients with renal impairment. 5.2 Allergic Reactions to Thiamine Allergic reactions such as urticaria, shortness of breath, wheezing and angioedema have been reported following intravenous administration of thiamine, which is found in INFUVITE ADULT. There have been rare reports of anaphylactoid reactions following intravenous doses of thiamine. No fatal anaphylactoid reactions associated with INFUVITE ADULT have been reported. 5.3. Hypervitaminosis A Hypervitaminosis A, manifested by nausea, vomiting, headache, dizziness, blurred vision has been reported in patients with renal failure receiving 1.5 mg/day retinol and in patients with liver disease, Therefore, supplementation of renal failure patients and patients with liver disease with vitamin A, an ingredient found in INFUVITE ADULT, should be undertaken with caution [see Use in Specific Populations ( 8.6 and 8.7 )]. 5.4 Decreased Anticoagulant Effect of Warfarin INFUVITE ADULT contains Vitamin K, which may decrease the anticoagulant action of warfarin. In patients who are on warfarin anticoagulant therapy receiving INFUVITE ADULT monitor blood levels of prothrombin/INR to determine if dose of warfarin needs to be adjusted. 5.5 Interference with Diagnosis of Megaloblastic Anemia INFUVITE ADULT contains folic acid and cyanocobalamin which can mask serum deficiencies of folic acid and cyanocobalamin in patients with megaloblastic anemia. Avoid the use of INFUVITE ADULT in patients with suspected or diagnosed megaloblastic anemia prior to blood sampling for the detection of the folic acid and cyanocobalamin deficiencies. 5.6 Potential to Develop Vitamin Deficiencies or Excesses In patients receiving parenteral multivitamins such as with INFUVITE ADULT, blood concentration should be periodically monitored to determine if deficiencies or excesses are developing. INFUVITE ADULT may not correct long-standing specific vitamin deficiencies. The administration of additional therapeutic doses of specific vitamins may be required [see Dosage and Administration ( 2.3 )]. 5.7 Interference with Urine Glucose Testing INFUVITE ADULT contains vitamin C which is also known as ascorbic acid. Ascorbic acid in the urine may cause false negative urine glucose results."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity, mutagenicity, and fertility studies have not been performed with INFUVITE ADULT."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Instruct patients (if age appropriate) and caregivers: • To watch for signs of allergic reactions such as urticaria, shortness of breath, wheezing and angioedema since hypersensitivity reactions may occur to any of the vitamins or excipients contained in INFUVITE ADULT. • To watch for and immediately report nausea, vomiting, headache, dizziness, blurred vision, especially if patients have renal impairment, as these may be signs of hypervitaminosis A. • To report other adverse reactions such as rash, erythema, pruritus, headache, dizziness, agitation, anxiety, and diplopia. • That the patients on warfarin anticoagulant therapy will be monitored periodically with blood prothrombin/ INR levels to determine if their dose of warfarin needs to be adjusted. • About the significance of periodic monitoring of blood vitamin concentrations to determine if vitamin deficiencies or excesses are developing and the need to monitor renal function, calcium, phosphorus, aluminum and vitamin A levels in patients with renal impairment. • That INFUVITE ADULT should be avoided in patients with suspected or diagnosed megaloblastic anemia prior to blood sampling for the detection of the folic acid and cyanocobalamin deficiencies. • That vitamin C (ascorbic acid) contained in INFUVITE ADULT may cause false negative urine glucose results. Manufactured for Sandoz Inc. , Princeton, NJ 08540 Distributed by Baxter Healthcare Corporation Deerfield, IL 60015 USA INFUVITE is a registered trademark of Sandoz Canada Inc. 5001527"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • INFUVITE ADULT is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K 1 , folic acid, biotin, and vitamin B 12 ( 2.1 ) • INFUVITE ADULT is for administration by intravenous infusion after dilution ( 2.1 ) • Recommended daily dosage is 10 mL ( 2.1 ) • INFUVITE ADULT is supplied as a single dose and as a pharmacy bulk package. o Single Dose : Add one daily dose of 10 mL (5 mL from Vial 1 and 5 mL from Vial 2) to not less than 500 mL, and preferably 1000 mL, of intravenous dextrose, saline or similar infusion solutions. ( 2.2 ) o Pharmacy Bulk Package : Add the contents of Vial 1 to the contents of Vial 2. This provides ten 10 mL daily doses. Take 10 mL from Vial 2 and add to not less than 500 mL, and preferably 1000 mL, of intravenous dextrose, saline or similar infusion solutions. ( 2.2 ) • After dilution in an intravenous infusion, refrigerate resulting solution unless used immediately. Use solution within 24 hours after dilution ( 2.2 ) • Monitor blood vitamin concentrations ( 2.3 ) • See Full Prescribing Information for drug incompatibilities ( 2.4 ) 2.1 Important Dosage Instructions INFUVITE ADULT is a combination product that contains the following vitamins: ascorbic acid, vitamin A, vitamin D, thiamine, riboflavin, pyridoxine, niacinamide, dexpanthenol, vitamin E, vitamin K 1 , folic acid, biotin, and vitamin B 12 . INFUVITE ADULT is supplied as a single dose or as a pharmacy bulk package for intravenous use intended for administration by intravenous infusion after dilution. INFUVITE ADULT Single Dose: • Provides one daily dose of 10 mL (5 mL of Vial 1 plus 5 mL of Vial 2) which must be diluted prior to intravenous administration [see Dosage and Administration ( 2.2 )] . INFUVITE ADULT Pharmacy Bulk Package: • Provides ten 10 mL daily doses when the content of vial 1 is transferred into the content of vial 2. One 10 mL dose is then added directly to intravenous fluid. Pharmacy bulk package of INFUVITE ADULT is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion [see Dosage and Administration ( 2.2 )]. Patients with multiple vitamin deficiencies or with increased vitamin requirements may need multiple daily dosages as indicated. Some patients do not maintain adequate levels of certain vitamins when this formulation in recommended amounts is the only source of vitamins. 2.2 Preparation and Administration Instructions Do not administer INFUVITE ADULT as a direct, undiluted intravenous injection as it may cause dizziness, faintness, and possible tissue irritation . INFUVITE ADULT Single Dose : • Use only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). • Add 5 mL of Vial 1 and 5 mL of Vial 2 to at least 500 mL to 1000 mL, of intravenous dextrose or saline solutions. • Discard unused portion. • Visually inspect for particulate matter and discoloration prior to administration. • After INFUVITE ADULT is diluted in an intravenous infusion, refrigerate the resulting solution unless it is to be used immediately, and use the solution within 24 hours after dilution. • Minimize exposure to light because some of the vitamins in INFUVITE ADULT, particularly A, D and riboflavin, are light sensitive. INFUVITE ADULT Pharmacy Bulk Package : • Use only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). • Transfer the contents of Vial 1 into the contents of Vial 2 to provide ten 10 mL single doses. • Each bulk vial closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. • Once the closure system has been penetrated, complete dispensing from the pharmacy bulk vial should be completed within 4 hours. The mixed solution may be refrigerated and stored for up to 4 hours. • Discard unused portion. • Visually inspect for particulate matter and discoloration prior to administration. • One daily 10 mL dose should be added directly to at least 500 mL to 1000 mL, of intravenous dextrose, saline or similar infusion solutions. • After INFUVITE ADULT is diluted in an intravenous infusion, refrigerate the resulting solution unless it is to be used immediately, and use the solution within 24 hours after dilution. • Minimize exposure to light because some of the vitamins in INFUVITE ADULT, particularly A, D and riboflavin, are light sensitive. 2.3 Monitoring Vitamin Blood Levels Blood vitamin concentrations should be monitored to ensure maintenance of adequate levels, particularly in patients receiving parenteral multivitamins as the only source of vitamins for long periods of time. 2.4 Drug Incompatibilities • INFUVITE ADULT is not physically compatible with moderately alkaline solutions such as a sodium bicarbonate solution and other alkaline drugs such as acetazolamide sodium, aminophylline, ampicillin sodium, tetracycline HCl and chlorothiazide sodium. • Folic acid is unstable in the presence of calcium salts such as calcium gluconate. • Vitamin A and thiamine in INFUVITE ADULT may react with bisulfite solutions such as sodium bisulfite or vitamin K bisulfate. • Do not add INFUVITE ADULT directly to intravenous fat emulsions. • Consult appropriate references for additional listings of physical and chemical compatibility of solutions and drugs with the vitamin infusion when needed. If incompatibilities are identified, avoid admixture or Y-site administration with vitamin solutions."],"spl_product_data_elements":["Infuvite Adult multiple vitamins injection Infuvite Adult multiple vitamins injection ASCORBIC ACID ASCORBIC ACID VITAMIN A PALMITATE VITAMIN A CHOLECALCIFEROL CHOLECALCIFEROL THIAMINE HYDROCHLORIDE THIAMINE ION THIAMINE RIBOFLAVIN 5'-PHOSPHATE SODIUM RIBOFLAVIN 5'-PHOSPHATE PYRIDOXINE HYDROCHLORIDE PYRIDOXINE NIACINAMIDE NIACINAMIDE DEXPANTHENOL DEXPANTHENOL PHYTONADIONE PHYTONADIONE POLYSORBATE 80 SODIUM HYDROXIDE HYDROCHLORIC ACID WATER .ALPHA.-TOCOPHEROL ACETATE, DL- .ALPHA.-TOCOPHEROL, DL- Infuvite Adult multiple vitamins injection FOLIC ACID FOLIC ACID BIOTIN BIOTIN CYANOCOBALAMIN CYANOCOBALAMIN PROPYLENE GLYCOL ANHYDROUS CITRIC ACID SODIUM CITRATE, UNSPECIFIED FORM WATER Infuvite Adult multiple vitamins injection Infuvite Adult multiple vitamins injection ASCORBIC ACID ASCORBIC ACID VITAMIN A PALMITATE VITAMIN A CHOLECALCIFEROL CHOLECALCIFEROL THIAMINE HYDROCHLORIDE THIAMINE ION THIAMINE RIBOFLAVIN 5'-PHOSPHATE SODIUM RIBOFLAVIN 5'-PHOSPHATE PYRIDOXINE HYDROCHLORIDE PYRIDOXINE NIACINAMIDE NIACINAMIDE DEXPANTHENOL DEXPANTHENOL PHYTONADIONE PHYTONADIONE POLYSORBATE 80 SODIUM HYDROXIDE HYDROCHLORIC ACID WATER .ALPHA.-TOCOPHEROL ACETATE, DL- .ALPHA.-TOCOPHEROL, DL- Infuvite Adult multiple vitamins injection FOLIC ACID FOLIC ACID BIOTIN BIOTIN CYANOCOBALAMIN CYANOCOBALAMIN PROPYLENE GLYCOL ANHYDROUS CITRIC ACID SODIUM CITRATE, UNSPECIFIED FORM WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS INFUVITE ADULT Single Dose: is an injection for intravenous administration consisting of two vials labeled Vial 1 (5 mL) and Vial 2 (5 mL). For the vitamin strengths [see Description ( 11 )]. INFUVITE ADULT Pharmacy Bulk Package : is an injection for intravenous administration consisting of two vials labeled Vial 1 (50 mL) and Vial 2 (50 mL Fill in 100 mL Vial). The mixed solution (100 mL) will provide ten 10 mL single doses. For the vitamin strengths [see Description ( 11 )]. Vial 1 (Single Dose and Pharmacy Bulk Package) is supplied as clear, yellow to orange liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a white flip-off. Vial 2 (Single Dose and Pharmacy Bulk Package) is supplied as clear, colorless to pale yellow liquid in amber glass vial closed with a rubber stopper, clear aluminum seal and a deep purple flip-off. • INFUVITE ADULT supplied as single dose is an injection consisting of two vials labeled Vial 1 (5 mL) and Vial 2 (5 mL) ( 3 ) • INFUVITE ADULT supplied as a pharmacy bulk package is an injection consisting of two vials labeled Vial 1 (50 mL) and Vial 2 (50 mL fill in 100 mL Vial) ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Pregnancy and Lactation: Pregnant and lactating patients should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonpregnant and nonlactating patients ( 8.1 , 8.2 ) • Renal Impairment: Monitor renal function, calcium, phosphorus and vitamin A levels in patients with renal impairment ( 8.6 ) • Hepatic Impairment: Monitor vitamin A level in patients with liver disease, high alcohol consumption ( 8.7 ) 8.1 Pregnancy Risk Summary Administration of the approved recommended dose of INFUVITE ADULT in parental nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Pregnant patients should follow the U.S. Recommended Daily Allowances for pregnancy because their vitamin requirements may exceed those of nonpregnant patients. Deficiency of essential vitamins may result in adverse pregnancy outcomes (see Clinical Considerations) . Animal reproduction studies have not been conducted with INFUVITE ADULT. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo-Fetal Risk Deficiency of essential vitamins has been associated with adverse pregnancy and fetal outcomes, such as maternal folic acid deficiency and an increased risk of neural tube defects. Therefore, parenteral nutrition with multiple vitamins injection should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. 8.2 Lactation Risk Summary Multiple vitamins present in INFUVITE ADULT are also present in human milk. Administration of the approved recommended dose of INFUVITE ADULT In parental nutrition is not expected to cause harm to a breastfed infant. There is no information on the effects of INFUVITE ADULT on milk production. Lactating patients should follow the U.S. Recommended Daily Allowances for their condition, because their vitamin requirements may exceed those of nonlactating patients. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for INFUVITE ADULT and any potential adverse effects on the breastfed child from INFUVITE ADULT or from the underlying maternal condition. 8.4 Pediatric Use Safety and effectiveness in children below the age of 11 years have not been established. 8.5 Geriatric Use Safety and effectiveness for geriatric use have not been established. 8.6 Renal Impairment INFUVITE ADULT has not been studied in patients with renal impairment. Monitor renal function, calcium, phosphorus and vitamin A levels in patients with renal impairment [see Warnings and Precautions ( 5.1 and 5.3 )]. 8.7 Hepatic Impairment INFUVITE ADULT has not been studied in patients with liver impairments. Monitor vitamin A level in patients with liver disease, high alcohol consumption [see Warnings and Precautions ( 5.3 )]."],"package_label_principal_display_panel":["Infuvite Adult Single Dose Vials Carton NDC 54643-5649-1 Rx Only Sterile INFUVITE ® ADULT (multiple vitamins injection) Contents: Five of Vial 1 (5 mL) and Five of Vial 2 (5 mL). One vial of each to be used for a single dose. Discard Unused Portion. For Intravenous Infusion Must be diluted before use. Baxter adult-single-dose-carton","Infuvite Adult Pharmacy Bulk Vials Carton NDC 54643-5650-2 Rx Only Sterile INFUVITE® ADULT (multiple vitamins injection) PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION Contents: One Vial 1 (50 mL) and One Vial 2 (50 mL fill in 100 mL Vial). Both vials combined produce 10 single doses. Discard Unused Portion For Intravenous Infusion Must be diluted before use. Baxter infuvite-adult-pbp-carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity, mutagenicity, and fertility studies have not been performed with INFUVITE ADULT."]},"tags":[{"label":"Vitamin D","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Vitamin D3 receptor","category":"target"},{"label":"VDR","category":"gene"},{"label":"GLRA1","category":"gene"},{"label":"CYP27B1","category":"gene"},{"label":"A11CC05","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Active","category":"status"},{"label":"Glucocorticoid Induced Osteoporosis","category":"indication"},{"label":"Hypocalcemia","category":"indication"},{"label":"Hypogonadal Osteoporosis in Males","category":"indication"},{"label":"Hypoparathyroidism","category":"indication"},{"label":"Osteomalacia","category":"indication"},{"label":"Osteoporosis","category":"indication"},{"label":"Sandoz","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Bone Density Conservation Agents","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Micronutrients","category":"pharmacology"},{"label":"Vitamins","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":2436.093,"date":"","count":1433,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 1,433 times (LLR=2436)"},{"llr":2167.68,"date":"","count":253,"signal":"Completed suicide","source":"DrugCentral FAERS","actionTaken":"Reported 253 times (LLR=2168)"},{"llr":1335.66,"date":"","count":255,"signal":"Drug abuse","source":"DrugCentral FAERS","actionTaken":"Reported 255 times (LLR=1336)"},{"llr":1127.988,"date":"","count":5416,"signal":"Pemphigus","source":"DrugCentral FAERS","actionTaken":"Reported 5,416 times (LLR=1128)"},{"llr":1115.184,"date":"","count":5898,"signal":"Systemic lupus erythematosus","source":"DrugCentral FAERS","actionTaken":"Reported 5,898 times (LLR=1115)"},{"llr":974.136,"date":"","count":6083,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 6,083 times (LLR=974)"},{"llr":954.292,"date":"","count":5069,"signal":"Glossodynia","source":"DrugCentral FAERS","actionTaken":"Reported 5,069 times (LLR=954)"},{"llr":917.302,"date":"","count":2911,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 2,911 times (LLR=917)"},{"llr":895.263,"date":"","count":8108,"signal":"Alopecia","source":"DrugCentral FAERS","actionTaken":"Reported 8,108 times (LLR=895)"},{"llr":859.888,"date":"","count":234,"signal":"Intentional overdose","source":"DrugCentral FAERS","actionTaken":"Reported 234 times (LLR=860)"},{"llr":805.026,"date":"","count":8189,"signal":"Abdominal discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 8,189 times (LLR=805)"},{"llr":800.002,"date":"","count":6701,"signal":"Rheumatoid arthritis","source":"DrugCentral FAERS","actionTaken":"Reported 6,701 times (LLR=800)"},{"llr":756.143,"date":"","count":6118,"signal":"Arthropathy","source":"DrugCentral FAERS","actionTaken":"Reported 6,118 times (LLR=756)"},{"llr":741.061,"date":"","count":4363,"signal":"Hand deformity","source":"DrugCentral FAERS","actionTaken":"Reported 4,363 times (LLR=741)"},{"llr":713.374,"date":"","count":16606,"signal":"Pain","source":"DrugCentral FAERS","actionTaken":"Reported 16,606 times (LLR=713)"}],"commonSideEffects":[{"effect":"Toxicity to various agents","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Completed suicide","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Drug abuse","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Pemphigus","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Systemic lupus erythematosus","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Glossodynia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Drug interaction","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Alopecia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Abdominal discomfort","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Rheumatoid arthritis","drugRate":"LLR 800","severity":"serious","_validated":true},{"effect":"Arthropathy","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Hand deformity","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Pain","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3}],"contraindications":["Achalasia of esophagus","Acute nephropathy","Acute peptic ulcer","Anemia due to enzyme deficiency","Arteriosclerosis obliterans","Aseptic necrosis of bone of jaw","Atrial fibrillation","Bed-ridden","Blood coagulation disorder","Carcinoma of female breast","Central nervous system depression","Constipation","Dehydration","Dental fluorosis","Diabetes mellitus","Diarrhea","Disease of liver","Duodenitis","Dysphagia","Esophageal Obstruction","Esophageal dysmotility","Esophagitis","Fracture of femur","Gastritis","Hb SS disease"]},"trials":[],"aliases":["Vitamin D3, CAS No: 67-97-0, ATC code: A11CC05","(Dekristol®, Swiss-Caps, Switzerland)","Vitamin D"],"company":"Novartis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Colecalciferol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:15:20.290118+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Colecalciferol","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:15:27.052404+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:15:25.605460+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Colecalciferol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:15:26.000411+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:15:18.845189+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vitamin D receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:15:27.052351+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1042/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:15:26.718318+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA021163","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:15:18.845223+00:00"}},"allNames":"infuvite adult","offLabel":[],"synonyms":["Vitamin D3","cholecalciferol","arachitol","calciol","calcirol","colecalciferol"],"timeline":[{"date":"2000-05-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sandoz)"}],"approvals":[{"date":"2000-05-18","orphan":false,"company":"SANDOZ","regulator":"FDA"}],"brandName":"Infuvite Adult","ecosystem":[{"indication":"Glucocorticoid Induced Osteoporosis","otherDrugs":[{"name":"alendronic acid","slug":"alendronic-acid","company":"Merck And Co Inc"},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"},{"name":"risedronic acid","slug":"risedronic-acid","company":"Warner Chilcott Llc"},{"name":"teriparatide","slug":"teriparatide","company":"Lilly"}],"globalPrevalence":200000000},{"indication":"Hypocalcemia","otherDrugs":[{"name":"calcifediol","slug":"calcifediol","company":""},{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"calcium acetate","slug":"calcium-acetate","company":"B Braun"},{"name":"calcium carbonate","slug":"calcium-carbonate","company":"Mcneil Cons"}],"globalPrevalence":null},{"indication":"Hypogonadal Osteoporosis in Males","otherDrugs":[{"name":"alendronic acid","slug":"alendronic-acid","company":"Merck And Co Inc"},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"},{"name":"teriparatide","slug":"teriparatide","company":"Lilly"},{"name":"zoledronic acid","slug":"zoledronic-acid","company":"Novartis"}],"globalPrevalence":200000000},{"indication":"Hypoparathyroidism","otherDrugs":[{"name":"calcitriol","slug":"calcitriol","company":"Validus Pharms"},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"},{"name":"parathyroid hormone","slug":"parathyroid-hormone","company":"Nps Pharms Inc"}],"globalPrevalence":null},{"indication":"Osteomalacia","otherDrugs":[{"name":"burosumab","slug":"burosumab","company":"Ultragenyx Pharm Inc"},{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"}],"globalPrevalence":56000},{"indication":"Osteoporosis","otherDrugs":[{"name":"abaloparatide","slug":"abaloparatide","company":"Radius Health Inc"},{"name":"calcium citrate","slug":"calcium-citrate","company":""},{"name":"calcium gluconate","slug":"calcium-gluconate","company":""},{"name":"calcium phosphate","slug":"calcium-phosphate","company":""}],"globalPrevalence":200000000},{"indication":"Postmenopausal osteoporosis","otherDrugs":[{"name":"alendronic acid","slug":"alendronic-acid","company":"Merck And Co Inc"},{"name":"bazedoxifene","slug":"bazedoxifene","company":"Wyeth Pharms Pfizer"},{"name":"calcitonin (salmon synthetic)","slug":"calcitonin-(salmon-synthetic)","company":"Sanofi Aventis Us"},{"name":"calcium citrate","slug":"calcium-citrate","company":""}],"globalPrevalence":200000000},{"indication":"Prevention of dental caries","otherDrugs":[{"name":"ergocalciferol","slug":"ergocalciferol","company":"Sanofi Aventis Us"},{"name":"potassium nitrate","slug":"potassium-nitrate","company":""},{"name":"retinol","slug":"retinol","company":"Hospira"},{"name":"sodium fluoride","slug":"sodium-fluoride","company":"Colgate Palmolive"}],"globalPrevalence":null}],"mechanism":{"target":"Vitamin D3 receptor","novelty":"Follow-on","targets":[{"gene":"VDR","source":"DrugCentral","target":"Vitamin D3 receptor","protein":"Vitamin D3 receptor"},{"gene":"GLRA1","source":"DrugCentral","target":"Glycine receptor subunit alpha-1","protein":"Glycine receptor subunit alpha-1"},{"gene":"CYP27B1","source":"DrugCentral","target":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial","protein":"25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial"},{"gene":"CYP27A1","source":"DrugCentral","target":"Sterol 26-hydroxylase, mitochondrial","protein":"Sterol 26-hydroxylase, mitochondrial"},{"gene":"CYP2R1","source":"DrugCentral","target":"Vitamin D 25-hydroxylase","protein":"Vitamin D 25-hydroxylase"}],"modality":"Small Molecule","drugClass":"Vitamin D","explanation":"","oneSentence":"","technicalDetail":"Infuvite Adult (Colecalciferol) acts as a selective vitamin D3 receptor agonist, activating the vitamin D receptor (VDR) to regulate the expression of genes involved in calcium homeostasis and bone metabolism."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cholecalciferol","title":"Cholecalciferol","extract":"Cholecalciferol, also known as vitamin D3, colecalciferol or calciol, is a skin-made vitamin D that is found in certain foods and used as a dietary supplement. It was first described in 1936, and is on the World Health Organization's List of Essential Medicines. In 2023, it was the 68th most commonly prescribed medication in the United States, with more than 9 million prescriptions, and is available as a generic medication."},"commercial":{"launchDate":"2000","_launchSource":"DrugCentral (FDA 2000-05-18, SANDOZ)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2840","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Colecalciferol","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Colecalciferol","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Cholecalciferol","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T10:16:36.893763","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:15:30.002098+00:00","fieldsConflicting":13,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ergocalciferol","drugSlug":"ergocalciferol","fdaApproval":"1941-01-11","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"calcitriol","drugSlug":"calcitriol","fdaApproval":"1978-08-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"calcifediol","drugSlug":"calcifediol","fdaApproval":"1980-08-05","patentExpiry":"Sep 7, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"colecalciferol","indications":{"approved":[{"name":"Glucocorticoid Induced Osteoporosis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Hypocalcemia","source":"DrugCentral","snomedId":5291005,"regulator":"FDA","eligibility":null},{"name":"Hypogonadal Osteoporosis in Males","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Hypoparathyroidism","source":"DrugCentral","snomedId":36976004,"regulator":"FDA","eligibility":null},{"name":"Osteomalacia","source":"DrugCentral","snomedId":4598005,"regulator":"FDA","eligibility":null,"prevalenceClass":"1-9 / 1 000 000","globalPrevalence":56000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (33818653[PMID]_ORPHANET)"},{"name":"Osteoporosis","source":"DrugCentral","snomedId":64859006,"regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Postmenopausal osteoporosis","source":"DrugCentral","snomedId":102447009,"regulator":"FDA","eligibility":null,"usPrevalence":10000000,"globalPrevalence":200000000,"prevalenceMethod":"curated","prevalenceSource":"IOF, 2023"},{"name":"Prevention of dental caries","source":"DrugCentral","snomedId":426482000,"regulator":"FDA","eligibility":null},{"name":"Rickets","source":"DrugCentral","snomedId":41345002,"regulator":"FDA","eligibility":null},{"name":"Vitamin D Dependent Rickets","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Vitamin D deficiency","source":"DrugCentral","snomedId":34713006,"regulator":"FDA"},{"name":"Vitamin deficiency","source":"DrugCentral","snomedId":85670002,"regulator":"FDA"}],"offLabel":[{"name":"Anticonvulsant-induced Osteomalacia","source":"DrugCentral","drugName":"Colecalciferol","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Renal osteodystrophy","source":"DrugCentral","drugName":"Colecalciferol","evidenceCount":693,"evidenceLevel":"strong"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ergocalciferol","brandName":"ergocalciferol","genericName":"ergocalciferol","approvalYear":"1941","relationship":"same-class"},{"drugId":"calcitriol","brandName":"calcitriol","genericName":"calcitriol","approvalYear":"1978","relationship":"same-class"},{"drugId":"calcifediol","brandName":"calcifediol","genericName":"calcifediol","approvalYear":"1980","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07494045","phase":"PHASE2","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants","status":"NOT_YET_RECRUITING","sponsor":"OPKO Health, Inc.","startDate":"2026-06","conditions":["CKD Stage 3","CKD Stage 4","Secondary Hyperparathyroidism","VDI"],"enrollment":40,"completionDate":"2028-08"},{"nctId":"NCT05933499","phase":"PHASE2","title":"Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-11-05","conditions":["Obesity"],"enrollment":63,"completionDate":"2029-03-31"},{"nctId":"NCT04615988","phase":"","title":"Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2021-06-09","conditions":["Thyroid","PD-1","Cancer"],"enrollment":17,"completionDate":"2028-06"},{"nctId":"NCT06610968","phase":"NA","title":"Acute Vitamin D Supplementation on Testosterone in Females","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2025-07-01","conditions":["Female Hormone Profile"],"enrollment":20,"completionDate":"2026-09-30"},{"nctId":"NCT07491965","phase":"","title":"Association Between Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency .","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03-01","conditions":["Benign Paroxysmal Positional Vertigo (BPPV)"],"enrollment":160,"completionDate":"2026-10-01"},{"nctId":"NCT07491601","phase":"NA","title":"PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery\"","status":"RECRUITING","sponsor":"Nicolas Schlegel","startDate":"2025-01-08","conditions":["Postoperative Hypoparathyroidism","Postsurgical Hypoparathyroidism","Hypoparathyroidism Post-surgical"],"enrollment":336,"completionDate":"2029-12-31"},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":["Triple Negative Breast Cancer","Vitamin D Deficiency","Invasive Breast Cancer"],"enrollment":50,"completionDate":"2026-08"},{"nctId":"NCT07356440","phase":"NA","title":"Effect of the Consumption of Cookies Enriched With Plant Proteins and of a Vitamin D Supplement on the Progression of Sarcopenia in the Elderly","status":"ENROLLING_BY_INVITATION","sponsor":"University of Udine","startDate":"2025-12-01","conditions":["Sarcopenia in Elderly","Sarcopenia","Nutritional Intervention","Microbiome Analysis","Muscle Mass and Strength","Biomarkers / Blood","Quality of Life Outcomes"],"enrollment":74,"completionDate":"2026-12"},{"nctId":"NCT07487610","phase":"","title":"Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older","status":"RECRUITING","sponsor":"Sultan 1. Murat State Hospital","startDate":"2026-03-17","conditions":["Neuropathic Pain","Old Age; Debility","Pain"],"enrollment":450,"completionDate":"2026-06-30"},{"nctId":"NCT07460336","phase":"NA","title":"Effects of Cofrogliptin on Beta-Cell Function in LADA Patients","status":"NOT_YET_RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2026-03-15","conditions":["Latent Autoimmune Diabetes in Adults (LADA)"],"enrollment":84,"completionDate":"2027-12-31"},{"nctId":"NCT07486141","phase":"NA","title":"Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Capital Medical University","startDate":"2024-11-01","conditions":["Mild Cognitive Impairment"],"enrollment":380,"completionDate":"2026-06"},{"nctId":"NCT06969716","phase":"","title":"Frequency of Fibromyalgia Syndrome in Elderly Patients Aged 80 and Above and Its Relationship With Geriatric Parameters","status":"COMPLETED","sponsor":"Sultan 1. Murat State Hospital","startDate":"2025-05-01","conditions":["Fibromyalgia","Old Age; Debility"],"enrollment":420,"completionDate":"2026-03-03"},{"nctId":"NCT02889081","phase":"","title":"Maternal Key Nutritional Factors and Offspring's Atopic Dermatitis (MKNFOAD)","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2016-06","conditions":["Atopic Dermatitis"],"enrollment":487,"completionDate":"2018-04-30"},{"nctId":"NCT00856947","phase":"PHASE1","title":"Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Studies on Asthma in Childhood","startDate":"2009-03","conditions":["Asthma"],"enrollment":600,"completionDate":"2027-07"},{"nctId":"NCT07479290","phase":"PHASE1","title":"Effect of Local Use of Vitamin D on the Rate of Canine Distillization: a Split Mouth Randomized Control Trial","status":"RECRUITING","sponsor":"Foundation University Islamabad","startDate":"2026-02-20","conditions":["Malocclusion of Anterior Teeth"],"enrollment":30,"completionDate":"2027-12"},{"nctId":"NCT07480369","phase":"NA","title":"Vegan Diet and Immune-Inflammatory Outcomes in Asthma and Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2026-03","conditions":["Asthma","Dietary Intervention","Vegan Diet"],"enrollment":280,"completionDate":"2029-09-30"},{"nctId":"NCT07479303","phase":"","title":"Vitamin D Status in Young Medical Residents","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-10-29","conditions":["Vitamin D Deficiency"],"enrollment":30,"completionDate":"2025-12-01"},{"nctId":"NCT07400757","phase":"NA","title":"Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease","status":"NOT_YET_RECRUITING","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2026-02-20","conditions":["Thyroid Eye Disease, TED","Graves Ophthalmopathy"],"enrollment":120,"completionDate":"2032-07-15"},{"nctId":"NCT07481240","phase":"NA","title":"A Household-Based Dietary Intervention Study of Vitamin D Fortified Bread in Irish Families","status":"RECRUITING","sponsor":"University College Cork","startDate":"2025-11-17","conditions":["Vitamin D Deficiency"],"enrollment":390,"completionDate":"2026-03-31"},{"nctId":"NCT06896669","phase":"NA","title":"Effects of Vitamin D and Calcium on Hyperglycemia and Dyslipidemia in Patients Gestational Diabetes","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2025-01-28","conditions":["Diabetes Mellitus, Gestational"],"enrollment":60,"completionDate":"2026-03-05"},{"nctId":"NCT05688956","phase":"NA","title":"Protein Supplement and Exercise Training for the Treatment of Sarcopenia Risk in Older Adults","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2023-02-01","conditions":["Sarcopenia"],"enrollment":46,"completionDate":"2025-05-31"},{"nctId":"NCT07241585","phase":"NA","title":"Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-05-01","conditions":["Nonmelanoma Skin Cancer","Basal Cell Carcinoma","Squamous Cell Carcinoma"],"enrollment":54,"completionDate":"2027-08"},{"nctId":"NCT06551285","phase":"NA","title":"Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome.","status":"RECRUITING","sponsor":"Celia Bañuls","startDate":"2024-02-01","conditions":["Polycystic Ovary Syndrome","Metabolic Syndrome"],"enrollment":120,"completionDate":"2029-05-31"},{"nctId":"NCT07292753","phase":"NA","title":"Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-12-15","conditions":["Nocturnal Enuresis","Vitamin D Deficiency"],"enrollment":90,"completionDate":"2025-10-10"},{"nctId":"NCT07467161","phase":"","title":"Relationship Between Insulin Resistance and Vitamin D in Type 2 Diabetes Mellitus (DM)","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03","conditions":["Type 2 Diabetes"],"enrollment":165,"completionDate":"2028-03"},{"nctId":"NCT01480869","phase":"PHASE3","title":"Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2011-07","conditions":["Breast Cancer"],"enrollment":215,"completionDate":"2014-12"},{"nctId":"NCT06515548","phase":"PHASE1","title":"Assessment of the Remineralization Efficacy of Vitamin D in the Treatment of MIH and Its Role in Improving Oral Hygiene and Gingival Health. In Situ Randomized Double-Blind Placebo CT","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-08-30","conditions":["Molar Incisor Hypomineralization"],"enrollment":32,"completionDate":"2025-03-30"},{"nctId":"NCT07468721","phase":"NA","title":"Effect of Vitamin D Supplementation on Metabolic Parameters in Patients With Type 2 Diabetes and Vitamin D Deficiency","status":"COMPLETED","sponsor":"Faculty of Medical Sciences, Clinical Hospital","startDate":"2024-05-07","conditions":["Type 2 Diabetes Mellitus (T2DM)","Vitamin D Deficiency"],"enrollment":119,"completionDate":"2025-03-31"},{"nctId":"NCT07465497","phase":"NA","title":"Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Instituto Jalisciense de Cancerologia","startDate":"2026-02-27","conditions":["Chemobrain","Breast Cancer","Inflammatory Disease"],"enrollment":80,"completionDate":"2027-02"},{"nctId":"NCT07052890","phase":"NA","title":"Curcumin, Vitamin D and Green Tea in IBS-D","status":"COMPLETED","sponsor":"Dr Anthony Hobson","startDate":"2024-09-19","conditions":["Irritable Bowel Syndrome (IBS)","Irritable Bowel Syndrome With Diarrhea (IBS-D)"],"enrollment":78,"completionDate":"2026-01-30"},{"nctId":"NCT05329428","phase":"NA","title":"PREDIN: Pregnancy and Vitamin D Intervention Study","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2022-04-14","conditions":["Vitamin D Deficiency","Vitamin D3 Deficiency","Pregnancy Complications"],"enrollment":105,"completionDate":"2024-09-16"},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":["COPD"],"enrollment":96,"completionDate":"2029-03-02"},{"nctId":"NCT07391254","phase":"NA","title":"Omega-3 Supplementation and Mental Health in College Students","status":"COMPLETED","sponsor":"University of Colorado, Colorado Springs","startDate":"2024-08-29","conditions":["Mental Health","Vitamin D"],"enrollment":103,"completionDate":"2025-12-12"},{"nctId":"NCT06250283","phase":"NA","title":"Resveratrol for the Prevention of Bone Loss in Postmenopausal Women","status":"COMPLETED","sponsor":"University of Delaware","startDate":"2024-02-02","conditions":["Low Bone Mass"],"enrollment":52,"completionDate":"2026-01-30"},{"nctId":"NCT07448844","phase":"PHASE4","title":"Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir","status":"RECRUITING","sponsor":"Riphah International University","startDate":"2026-02-20","conditions":["Viral Wart","Plantar Wart","Common Warts (Verruca Vulgaris)","Common Wart","Flat Wart","Warts of Foot","Warts Hand","Wart"],"enrollment":40,"completionDate":"2026-05-20"},{"nctId":"NCT06780202","phase":"PHASE2","title":"Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-27","conditions":["Foot Injuries and Disorders","Ankle Injuries and Disorders","Achilles Tendon Injury"],"enrollment":180,"completionDate":"2027-12"},{"nctId":"NCT07458815","phase":"NA","title":"Vitamin D for Acute Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-01","conditions":["Intracerebral Hemorrhage"],"enrollment":40,"completionDate":"2028-02-28"},{"nctId":"NCT07455656","phase":"NA","title":"Assessment of the Locally Administrated Vitamin D3 and Corticision Efficacy on Orthodontic Canine Retraction","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2025-08-01","conditions":["Malocclusions","Canine Retraction"],"enrollment":16,"completionDate":"2027-08-01"},{"nctId":"NCT05683990","phase":"PHASE2","title":"Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes","status":"RECRUITING","sponsor":"Diamyd Medical AB","startDate":"2024-07-09","conditions":["Diabetes Mellitus, Type 1","Autoimmune Diseases","Prevention"],"enrollment":16,"completionDate":"2028-03-31"},{"nctId":"NCT07453238","phase":"PHASE4","title":"Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-04-01","conditions":["Alopecia Areata"],"enrollment":60,"completionDate":"2026-10-01"},{"nctId":"NCT07345884","phase":"NA","title":"Treatment of Severe Acute Malnutrition in Children 6 to 59 Months Old With Standard Ready To Use Therapeutic Food Compared to a Newly Formulated Lipid Optimized Ready To Use Therapeutic Food","status":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-02","conditions":["Severe Acute Malnutrition in Childhood","Malnutrition, Child","Neurocognition, Child"],"enrollment":125,"completionDate":"2026-06"},{"nctId":"NCT07448974","phase":"PHASE3","title":"Vitamin D and Type 2 Diabetes - Treat-To-Target","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-05","conditions":["Prediabetes","Type 2 Diabetes (T2DM)"],"enrollment":100,"completionDate":"2031-03"},{"nctId":"NCT07450079","phase":"","title":"Characterising Sleep Disorders in Children With Tourette Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Steffi Baker","startDate":"2026-03-01","conditions":["Tourette Syndrome"],"enrollment":34,"completionDate":"2027-09-30"},{"nctId":"NCT04094688","phase":"PHASE3","title":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-10-29","conditions":["Colorectal Adenocarcinoma"],"enrollment":455,"completionDate":"2026-07-01"},{"nctId":"NCT07439874","phase":"NA","title":"Genetic Alterations From Physical Therapy in Low Back Pain and Disc Degeneration","status":"COMPLETED","sponsor":"University of Tabuk","startDate":"2024-08-15","conditions":["Genetic Alteration","Low Back Pain","Physiotherapy"],"enrollment":200,"completionDate":"2026-01-15"},{"nctId":"NCT05869812","phase":"PHASE2","title":"Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2023-05-29","conditions":["Atrophy"],"enrollment":30,"completionDate":"2029-12"},{"nctId":"NCT05045066","phase":"EARLY_PHASE1","title":"Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-12-29","conditions":["Localized Prostate Carcinoma","Stage IV Prostate Cancer AJCC v8","Locally Recurrent Prostate Carcinoma","Metastatic Prostate Carcinoma"],"enrollment":220,"completionDate":"2029-08-31"},{"nctId":"NCT03633708","phase":"PHASE3","title":"A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis","status":"RECRUITING","sponsor":"Amgen","startDate":"2019-04-29","conditions":["Secondary Hyperparathyroidism","Chronic Kidney Disease"],"enrollment":56,"completionDate":"2029-01-31"},{"nctId":"NCT07435935","phase":"","title":"Bone Myoregulation Reflex and Postural Control in Vitamin D Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Istanbul Physical Medicine Rehabilitation Training and Research Hospital","startDate":"2026-03-05","conditions":["Vitamin D Deficiency"],"enrollment":24,"completionDate":"2026-07-05"},{"nctId":"NCT06697626","phase":"NA","title":"Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Ulster","startDate":"2024-11-14","conditions":["Constipation","Parkinson Disease"],"enrollment":56,"completionDate":"2026-11"},{"nctId":"NCT05125809","phase":"PHASE2,PHASE3","title":"Setrusumab vs Placebo for Osteogenesis Imperfecta","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2022-02-21","conditions":["Osteogenesis Imperfecta"],"enrollment":183,"completionDate":"2027-04"},{"nctId":"NCT05018585","phase":"PHASE3","title":"A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diamyd Medical AB","startDate":"2022-05-19","conditions":["Type 1 Diabetes Mellitus"],"enrollment":330,"completionDate":"2027-12"},{"nctId":"NCT04355572","phase":"NA","title":"Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-05","conditions":["Polycystic Ovarian Syndrome in Adolescent Females","Vitamin D Deficiency"],"enrollment":60,"completionDate":"2027-12-01"},{"nctId":"NCT06508333","phase":"NA","title":"Efficacy and Safety of Vitamin D Supplementation Combined With Alarm Therapy in Treating Nocturnal Enuresis","status":"COMPLETED","sponsor":"Xing Liu","startDate":"2024-12-01","conditions":["Enuresis"],"enrollment":262,"completionDate":"2025-05-31"},{"nctId":"NCT04868903","phase":"NA","title":"Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-11-30","conditions":["SARS-CoV-2 Infection"],"enrollment":1475,"completionDate":"2024-12-01"},{"nctId":"NCT07424911","phase":"","title":"α-N-acetylgalactosaminidase Levels in Panic Disorder","status":"COMPLETED","sponsor":"Elazığ Mental Health and Diseases Hospital","startDate":"2025-05-01","conditions":["Panic Disorder"],"enrollment":66,"completionDate":"2025-08-01"},{"nctId":"NCT07347743","phase":"NA","title":"Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns.","status":"RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2026-01-31","conditions":["Colic","Healthy Infants","Eczema Atopic Dermatitis"],"enrollment":768,"completionDate":"2028-12"},{"nctId":"NCT04036188","phase":"EARLY_PHASE1","title":"Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis","status":"RECRUITING","sponsor":"Wright State University","startDate":"2019-10-16","conditions":["Plaque Psoriasis","Vitamin D3"],"enrollment":24,"completionDate":"2026-12"},{"nctId":"NCT07419633","phase":"NA","title":"This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-02-05","conditions":["Muscle","Cognitive Functioning","Geriatric","Ageing and Geriatric Health","Ageing"],"enrollment":120,"completionDate":"2027-02-05"},{"nctId":"NCT05619289","phase":"PHASE2","title":"Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-04-12","conditions":["Burn Injury","Chronic Pain"],"enrollment":40,"completionDate":"2026-01-16"},{"nctId":"NCT07409623","phase":"","title":"Vitamin D Status in Hemodialysis Transplant Candidates and Living Donors","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-02-01","conditions":["Vitamin D Deficiency"],"enrollment":552,"completionDate":"2026-02-01"},{"nctId":"NCT07308288","phase":"NA","title":"Immune Nutrition in Pediatric Respiratory Allergy","status":"COMPLETED","sponsor":"Federico II University","startDate":"2025-06-01","conditions":["Asthma Acute","Allergic Rhinitis"],"enrollment":40,"completionDate":"2025-12-31"},{"nctId":"NCT06203041","phase":"NA","title":"Vitamin D Sulfates in Breastmilk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-21","conditions":["Vitamin D Deficiency","Breast Milk Collection"],"enrollment":60,"completionDate":"2027-12"},{"nctId":"NCT07415421","phase":"NA","title":"Parathyroidectomy After Kidney Transplantation","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2026-01-20","conditions":["Hyperparathyroidism","Kidney Transplantation Recipients"],"enrollment":85,"completionDate":"2030-12-31"},{"nctId":"NCT05058976","phase":"PHASE4","title":"Romosozumab Use to Build Skeletal Integrity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Susan L. Greenspan","startDate":"2021-09-15","conditions":["Osteoporosis","Osteoporosis, Postmenopausal","Osteoporosis Fracture"],"enrollment":184,"completionDate":"2027-03-31"},{"nctId":"NCT05877846","phase":"NA","title":"Precision Medicine and Physical Function","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-11-01","conditions":["Frailty","Weakness, Muscle","Multiple Chronic Conditions"],"enrollment":25,"completionDate":"2026-12-01"},{"nctId":"NCT05050916","phase":"PHASE2","title":"The Investigation of Vitamin D and Menstrual Cycles Trial, the inVitD Trial: A Phase II Clinical Trial","status":"COMPLETED","sponsor":"National Institute of Environmental Health Sciences (NIEHS)","startDate":"2023-03-17","conditions":["Reproductive Issues"],"enrollment":57,"completionDate":"2024-06-27"},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":["HELICOBACTER PYLORI INFECTIONS","Helicobacter Infection","Helicobacter Pylori Gastrointestinal Tract Infection","Helicobacter Pylori Infected Patients"],"enrollment":66,"completionDate":"2026-12-20"},{"nctId":"NCT05448365","phase":"NA","title":"Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid","status":"RECRUITING","sponsor":"Lo.Li.Pharma s.r.l","startDate":"2022-07-01","conditions":["Uterine Fibroids","D-chiro-inositol","Inositol","Epigallocatechin Gallate","Vitamin D","Vitamin B6"],"enrollment":60,"completionDate":"2026-07-01"},{"nctId":"NCT07401992","phase":"PHASE4","title":"Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2026-01-15","conditions":["Psoriasis (PsO)","Obesity & Overweight","Diabetes Mellitus - Type 2"],"enrollment":62,"completionDate":"2027-02-28"},{"nctId":"NCT05036109","phase":"NA","title":"DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-12","conditions":["Colorectal Cancer","Colon Cancer"],"enrollment":16,"completionDate":"2026-02-04"},{"nctId":"NCT01747447","phase":"NA","title":"VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2012-08","conditions":["Bone Density","Body Composition","Bone Health"],"enrollment":771,"completionDate":"2023-08-02"},{"nctId":"NCT04159675","phase":"","title":"Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-09-04","conditions":["Craniosynostoses"],"enrollment":20,"completionDate":"2026-04-04"},{"nctId":"NCT04394390","phase":"","title":"Vitamin D Levels in SARS-CoV-2: Do Current Adequacy Thresholds Reflect Clinical Risk? Insights From a Large Turkish Cohort","status":"COMPLETED","sponsor":"Bursa City Hospital","startDate":"2020-05-01","conditions":["COVID","Vitamin D Deficiency"],"enrollment":1100,"completionDate":"2025-08-30"},{"nctId":"NCT07245277","phase":"PHASE4","title":"Effect of Vitamin D as Adjuvant Therapy in Preterm Infants With Neonatal Sepsis","status":"COMPLETED","sponsor":"Fakultas Kedokteran Universitas Padjadjaran","startDate":"2025-08-02","conditions":["Neonatal Sepsis","Preterm Infants"],"enrollment":78,"completionDate":"2025-12-08"},{"nctId":"NCT07120997","phase":"NA","title":"Prunes Preventing Bone Loss in Perimenopause","status":"RECRUITING","sponsor":"Penn State University","startDate":"2025-12-11","conditions":["Perimenopausal Bone Loss"],"enrollment":124,"completionDate":"2029-12"},{"nctId":"NCT07385144","phase":"NA","title":"A Study of a Dietary Supplement on Serum Biomarkers in Children","status":"RECRUITING","sponsor":"SF Research Institute, Inc.","startDate":"2026-01-30","conditions":["Nutritional Status","Serum Biomarkers"],"enrollment":30,"completionDate":"2026-03-05"},{"nctId":"NCT07387458","phase":"","title":"Bone Turnover Markers and Vitamin D Survey Among Health Professionals in Taiwan","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2024-12-01","conditions":["Bone Remodeling","Vitamin D"],"enrollment":432,"completionDate":"2025-12-31"},{"nctId":"NCT06688994","phase":"","title":"Vitamin D Metabolites as Biomarkers for the Identification of Kidney Injury in Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-12-02","conditions":["Acute Kidney Injuries","Chronic Renal Diseases"],"enrollment":46,"completionDate":"2026-12-31"},{"nctId":"NCT06861062","phase":"NA","title":"Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-04-08","conditions":["Diabetes Mellitus, Type 2"],"enrollment":2500,"completionDate":"2032-12-31"},{"nctId":"NCT07381998","phase":"NA","title":"Effects of Total Thyroid Removal on Parathyroid Function and Quality of Life","status":"ENROLLING_BY_INVITATION","sponsor":"Aarhus University Hospital","startDate":"2026-01-01","conditions":["Hypoparathyroidism Post-surgical","Quality of Life"],"enrollment":150,"completionDate":"2028-12"},{"nctId":"NCT01704859","phase":"NA","title":"VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-06-01","conditions":["Fractures"],"enrollment":25871,"completionDate":"2022-11-23"},{"nctId":"NCT04871412","phase":"PHASE3","title":"The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-04-04","conditions":["Lung Cancer","Gastric Cancer","Esophageal Cancer"],"enrollment":20,"completionDate":"2029-12-01"},{"nctId":"NCT04573946","phase":"NA","title":"VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2019-07-01","conditions":["Bone Density","Bone Health","Fractures"],"enrollment":25871,"completionDate":"2026-12-31"},{"nctId":"NCT01698840","phase":"NA","title":"Effect of Vitamin D in Diets of Preterm Infants","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-01","conditions":["Premature Infants"],"enrollment":39,"completionDate":"2016-07-30"},{"nctId":"NCT03344718","phase":"","title":"Metabolic Syndrome and Vitamin D Level in Old People","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2012-07-30","conditions":["Elderly","Metabolic Syndrome","Vitamin D Deficiency","Ostreocalcin","Insulin Resistance","Obesity","Osteoporosis","Sarcopenia"],"enrollment":549,"completionDate":"2012-08-17"},{"nctId":"NCT03534934","phase":"NA","title":"CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD","status":"COMPLETED","sponsor":"Punam K Saha","startDate":"2019-02-26","conditions":["Pulmonary Disease, Chronic Obstructive","Osteoporosis"],"enrollment":560,"completionDate":"2025-03-19"},{"nctId":"NCT07369063","phase":"PHASE2","title":"Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-08-01","conditions":["Graves Disease","Graves' Disease","Hyperthyroidism"],"enrollment":30,"completionDate":"2027-02-28"},{"nctId":"NCT07013305","phase":"","title":"Pre- and Post-Treatment Investigation of B12 and Folic Acid (Folate) Levels in Patients Receiving Antiepileptic (Anticonvulsant) Treatment for Fibromyalgia: Retrospective Study","status":"COMPLETED","sponsor":"Gaziosmanpasa Research and Education Hospital","startDate":"2025-06-11","conditions":["Fibromyalgia (FM)","Vitamin B 12 Deficiency","Folic Acid Deficiency"],"enrollment":104,"completionDate":"2025-07-01"},{"nctId":"NCT07366086","phase":"PHASE3","title":"Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta","status":"NOT_YET_RECRUITING","sponsor":"Amgen","startDate":"2026-03-07","conditions":["Osteogenesis Imperfecta"],"enrollment":71,"completionDate":"2028-05-21"},{"nctId":"NCT07366970","phase":"NA","title":"Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D?","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-12-05","conditions":["Diabetes Mellitus","Erectile Dysfunction","Vitamin D Deficiency"],"enrollment":40,"completionDate":"2026-05-05"},{"nctId":"NCT07299838","phase":"","title":"Palopegteriparatide in Chronic Hypoparathyroidism","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2024-06-01","conditions":["Hypoparathyroidism"],"enrollment":90,"completionDate":"2025-10-23"},{"nctId":"NCT07366450","phase":"NA","title":"High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Phramongkutklao College of Medicine and Hospital","startDate":"2026-02-01","conditions":["Vitamin D 25-Hydroxylase Deficiency","Lymphoma Non-Hodgkin"],"enrollment":52,"completionDate":"2029-07-31"},{"nctId":"NCT06327581","phase":"NA","title":"Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata","status":"RECRUITING","sponsor":"Zagazig University","startDate":"2023-12-15","conditions":["Alopecia Areata"],"enrollment":88,"completionDate":"2026-12-30"},{"nctId":"NCT07364383","phase":"NA","title":"Probiotics for Women","status":"NOT_YET_RECRUITING","sponsor":"Cultech Ltd","startDate":"2026-01-09","conditions":["Probiotic","Microbiome","Wellbeing"],"enrollment":40,"completionDate":"2026-05-01"},{"nctId":"NCT05008484","phase":"PHASE2,PHASE3","title":"Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2021-10-01","conditions":["Spinal Cord Injury"],"enrollment":6,"completionDate":"2024-06-13"},{"nctId":"NCT07349290","phase":"NA","title":"Vitamin D (Bio)Fortified Shopping Baskets to Improve Vitamin D Status","status":"ENROLLING_BY_INVITATION","sponsor":"University of Ulster","startDate":"2026-01","conditions":["Vitamin D Biofortification","Vitamin D Fortification","Vitamin D Status"],"enrollment":160,"completionDate":"2027-04"},{"nctId":"NCT07352501","phase":"NA","title":"Effectiveness of Pulsed Electromagnetic Fields and Nutraceutical Supplementation in Women With Distal Radius Fracture","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Palermo","startDate":"2025-03-10","conditions":["Fracture of Distal Radius","Bone Fractures","Wrist Injuries"],"enrollment":100,"completionDate":"2026-03-15"},{"nctId":"NCT07288619","phase":"NA","title":"Therapeutic Efficacy of Nutritional Supplementation in Cachexia Associated With Chronic Pulmonary Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Safeer Khan","startDate":"2025-10-15","conditions":["Chronic Obstructive Pulmonary Disease (COPD)","Cachexia"],"enrollment":45,"completionDate":"2026-04-15"},{"nctId":"NCT07349459","phase":"NA","title":"Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-04-30","conditions":["Melatonin","Breast Cancer Patients Diagnosed","Vitamin D Concentration","Doxorubicin"],"enrollment":90,"completionDate":"2026-08-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Marnatal F"},{"form":"CAPSULE","route":"ORAL","productName":"Animi-3"},{"form":"CAPSULE","route":"ORAL","productName":"Animi-3 with Vitamin D"},{"form":"CAPSULE","route":"ORAL","productName":"Revesta"},{"form":"CAPSULE","route":"ORAL","productName":"Zyvana"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"CitraNatal Harmony"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"CitraNatal Harmony"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"C-Nate DHA"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"CitraNatal Harmony 3.0"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"CitraNatal Medley"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"Nestabs ONE"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"PNV-DHA"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"PNV-Omega"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"PRENATE DHA"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","productName":"PRENATE Enhance"}]},"crossReferences":{"MMSL":"15676","NDDF":"001014","UNII":"1C6V77QF41","CHEBI":"CHEBI:28940","VANDF":"4017667","INN_ID":"1497","RXNORM":"1244014","UMLSCUI":"C0008318","chemblId":"CHEMBL1042","ChEMBL_ID":"CHEMBL1042","KEGG_DRUG":"D00188","DRUGBANK_ID":"DB00169","PDB_CHEM_ID":" VD3","PUBCHEM_CID":"5280795","SNOMEDCT_US":"108943009","IUPHAR_LIGAND_ID":"2747","MESH_DESCRIPTOR_UI":"D002762"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","company":"Sandoz Manufacturing Inc","brandName":"Adult Infuvite Multiple Vitamins","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"2000-","companyName":"Sandoz","relationship":"Original Developer"}],"publicationCount":86,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"A11CC05","allCodes":["A11CC05","A11CC55","M05BB03","M05BB04","M05BB05","M05BB07","M05BB08","M05BB09","M05BX53"]},"biosimilarFilings":[],"originalDeveloper":"Sandoz","recentPublications":[{"date":"2025","pmid":"41235112","title":"Implementation of pharmacist recommendations following medication reviews in aged care.","journal":"Frontiers in pharmacology"},{"date":"2025 Sep","pmid":"40461338","title":"Novel approach to central giant cell granuloma of the Jaw: Low-dose intralesional denosumab treatment in a case series of nine patients.","journal":"Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery"},{"date":"2025 Aug","pmid":"40412099","title":"Effect of cholecalciferol on 25-hydroxyvitamin D in people living with HIV and vitamin D deficiency: A prospective observational study.","journal":"Medicina clinica"},{"date":"2025 Feb","pmid":"40034581","title":"Desensitization to colecalciferol in 18 patients with immediate hypersensitivity reactions.","journal":"The World Allergy Organization journal"},{"date":"2024 Jul 30","pmid":"39130432","title":"Repurposing anti-osteoporosis drugs for autoimmune diseases: A two-sample Mendelian randomization study.","journal":"Heliyon"}],"combinationProducts":[{"brandName":"Adult Infuvite Multiple Vitamins","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"},{"brandName":"Adult Infuvite Multiple Vitamins for Infusion","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"},{"brandName":"FOSAMAX PLUS D","ingredients":"alendronic acid + colecalciferol"},{"brandName":"Infuvite Adult Multiple Vitamins","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"},{"brandName":"PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"},{"brandName":"Pediatric Infuvite Multiple Vitamins","ingredients":"alpha-tocopherol acetate + ascorbic acid + biotin + colecalciferol + cyanocobalamin + dexpanthenol + folic acid + nicotinamide + phytomenadione + pyridoxine + thiamine + vitamin A palmitate"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"2000","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2000-05-18T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2000-05-18T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2000-05-18T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2000-05-18T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2000-05-18T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-05-18T00:00:00.000Z","mah":"SANDOZ","brand_name_local":null,"application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:15:30.002098+00:00","fieldsConflicting":13,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}